Panbela Therapeutics, Inc. filed a post-effective amendment to a Form S-1 registration statement with the Securities and Exchange Commission on March 29, 2024. The amendment pertains to the issuance of up to 8,750,000 shares of common stock underlying Class E and Class F common stock purchase warrants previously issued in a registered public offering. The shares are issuable upon exercise of the warrants at a price of $2.06 per share. The company's common stock is quoted on the OTC Pink Market under the symbol 'PBLA,' with the last reported sale price on March 26, 2024, being $0.64 per share. Panbela Therapeutics, a Delaware corporation with a primary standard industrial classification code number of 2834, is a clinical-stage biopharmaceutical company focused on developing treatments for patients with urgent unmet medical needs. The company's CEO is Jennifer K. Simpson, and its principal executive offices are located in Waconia, Minnesota. The proceeds from the exercise of the warrants are intended for the continued clinical development of Panbela's product candidates and for general corporate purposes.

Panbela Therapeutics, Inc. filed a post-effective amendment to a Form S-1 registration statement with the Securities and Exchange Commission on March 29, 2024. The amendment pertains to the issuance of up to 8,750,000 shares of common stock underlying Class E and Class F common stock purchase warrants previously issued in a registered public offering. The shares are issuable upon exercise of the warrants at a price of $2.06 per share. The company's common stock is quoted on the OTC Pink Market under the symbol 'PBLA,' with the last reported sale price on March 26, 2024, being $0.64 per share. Panbela Therapeutics, a Delaware corporation with a primary standard industrial classification code number of 2834, is a clinical-stage biopharmaceutical company focused on developing treatments for patients with urgent unmet medical needs. The company's CEO is Jennifer K. Simpson, and its principal executive offices are located in Waconia, Minnesota. The proceeds from the exercise of the warrants are intended for the continued clinical development of Panbela's product candidates and for general corporate purposes.